GENETEX: SARS-CoV-2 Omicron therapeutics
As SARS-CoV-2 Omicron variants continue to dominate around the world and accumulate novel mutations leading to immune evasion, antiviral treatments are becoming increasingly important to limit hospitalizations and death due to COVID-19. Studies are still lacking to understand which combination therapy approaches will have the greatest potency and synergy against SARS-CoV-2 Omicron sub-variants. Dr. Jean will present the recent discovery of novel pan-coronavirus antiviral drugs directed at viral and host-cell enzymes. He will discuss their applications as direct-acting antivirals (DAAs) and host-directed antivirals (HDAs) against SARS-CoV-2 Omicron variants when used alone or in combination in 2D and 3D cell-based systems of viral infection. This work will provide new insights into the unique biology of SARS-CoV-2 Omicron variants, and unravel potential combination antiviral therapies based on HDAs and DAAs acting synergistically as alternatives to monotherapy to improve COVID-19 treatment.
BIO X CELL COA
Cut Down Wait Time
Bio X Cell Certificate Of Analysis (COA) is now available to download, whenever you need it!
A NEW tool is now available to you, which allows you to download COA PDF files whenever your customers need them. Simply click the link below, and fill in the catalog number, lot number, vial size, and vial count. The COA of your request will be downloaded and ready to be shared with your customers immediately.
ARIGO GAINDATA
MIRUS REAGENT AGENT
The Transfection Experts bring you the Reagent Agent® - a tool designed to help you determine the best delivery solution for any nucleic acid into any cell type including hard-to-transfect cell lines and primary cells.
Reagent Agent® recommendations are based on extensive in-house transfection and electroporation data, customer feedback, and citations that are all continually updated.